Lumos Pharma, Inc.
LUMO
|
News
|
$2.57
-1.91%
-1.95%
12K
|
Health Technology
(0.0% 1d) (-14.0% 1m) (-17.6% 1y) (0.0% 2d) (0.0% 3d) (2.9% 7d) (-100.0% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 20,859,374
http://www.lumos-pharma.com
Sec Filling | Patents | 21 employees
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
hormone growth hormone treatment
add to watch list Paper trade email alert is off
Press-releases
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Published: 2024-04-18 (Crawled : 20:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
| Email alert
Add to watchlist
pharma presentation for medical
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: -4.7%
H: 12.62%
C: 12.62%
lum-201 pharma patent granted
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: -1.65%
H: 4.03%
C: 2.01%
pharma year update financial results
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
Published: 2024-02-26 (Crawled : 14:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: -2.67%
H: 4.45%
C: 4.11%
pharma conference report year financial results
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-05 (Crawled : 21:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: -1.61%
H: 1.64%
C: -1.31%
pharma conference life sciences
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: -2.24%
H: 4.58%
C: 4.58%
pharma medical
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
Published: 2023-11-21 (Crawled : 21:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: -1.64%
H: 4.66%
C: 2.67%
lum-201 pharma treatment trial potential growth hormone
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
Published: 2023-11-20 (Crawled : 21:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: -3.27%
H: 6.01%
C: 3.04%
pharma conference
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: 22.25%
H: 2.25%
C: -9.44%
pharma financial results
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
LUMO | News | $2.57 -1.91% -1.95% 12K
|
Health Technology
|
| O: 22.25%
H: 2.25%
C: -9.44%
lum-201 pharma trials topline
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001126234-24-000018 | 4 | 2024-02-07 | 2024-02-06 | Sell | S | 438 | 18403 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RKT | News P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA | $0.377 -1.4% 97K
|
Health Technology
|
22:00
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 0.0% 260K
|
Utilities
|
14:00
ETST P 39000 | $0.068 -67.14% 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K
|
Finance
|
12:30
ADMQ | $0.0532 -40.18% 480K
|
|
10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K
|
Finance
|
21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K
|
Finance
|
18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
18:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10